Product Pathways - Development
CUTL1 Antibody #81557
|81557S||100 µl ( 10 western blots )||￥3,100.00 现货查询||购买询价|
|81557||carrier free & custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation,
Specificity / Sensitivity
CUTL1 Antibody recognizes endogenous levels of total CUTL1 protein. It recognizes the p200 isoform (the full-length) and is not expected to recognize the p110 and p75 isoforms.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln639 of human CUTL1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
CUTL1 (Cut-like 1), also known as CUX1 (Cut homeobox 1) (CUX1), is a transcription factor that has been implicated in many cellular processes in different tissues, such as cell migration, neuronal differentiation, and DNA repair (1-5). CUTL1 expression and activities are altered in cancer. Research studies have shown the CUTL1 gene to be a frequent target of loss-of-heterozygocity in various cancers (6,7). On the other hand, CUTL1 expression is elevated in many cancers and is associated with shorter disease-free survival (8). These accumulating evidence suggest that decreased CUTL1 expression promote tumor initiation and increased CUTL1 expression facilitates tumor progression (9). While full-length CUTL1 is about 200 kDa (p200), short forms p110 and p75 can also be generated by proteolytic processing and alternative transcription initiation site, respectively (10, 11).
- Rodríguez-Tornos, F.M. et al. (2016) Neuron 89, 494-506.
- Ramdzan, Z.M. et al. (2015) Oncotarget 6, 3613-26.
- Ramdzan, Z.M. et al. (2014) PLoS Biol 12, e1001807.
- Kedinger, V. et al. (2009) J Biol Chem 284, 27701-11.
- Vadnais, C. et al. (2012) Nucleic Acids Res 40, 4483-95.
- McNerney, M.E. et al. (2013) Blood 121, 975-83.
- Ramdzan, Z.M. and Nepveu, A. (2014) Nat Rev Cancer 14, 673-82.
- Michl, P. et al. (2005) Cancer Cell 7, 521-32.
- Hulea, L. and Nepveu, A. (2012) Gene 497, 18-26.
- Moon, N.S. et al. (2001) Mol Cell Biol 21, 6332-45.
- Goulet, B. et al. (2002) Cancer Res 62, 6625-33.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 12630 SignalFire™ Plus ECL Reagent
- 12757 SignalFire™ Elite ECL Reagent
- 6883 SignalFire™ ECL Reagent
- 7074 Anti-rabbit IgG, HRP-linked Antibody
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
用户评论 --- 共 0 条